BIND Therapeutics (BIND) Tops Q4 EPS by 12c

BIND Therapeutics (NASDAQ: BIND) reported Q4 EPS of ($0.37), $0.12 better than the analyst estimate of ($0.49). Revenue for the quarter came in at $6.4 million versus the consensus estimate of $3.35 million.

For earnings history and earnings-related data on BIND Therapeutics (BIND) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15